Pathak Rima S, Pantarotto Jason R, Cook Graham, Holmes Oliver, Cross Peter, MacRae Robert M
Division of Radiation Oncology, The University of Ottawa, Ottawa, ON, The Ottawa Hospital Cancer Centre, Canada.
Discipline of Oncology, Dr. H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada.
Clin Transl Radiat Oncol. 2019 Jan 24;16:28-33. doi: 10.1016/j.ctro.2019.01.003. eCollection 2019 May.
•This study reports on the prognostic ability of haematological parameters for the largest known biopsy-proven stage-I medically inoperable cohort treated with SBRT.•After SBRT, the median values of Hb, ALC, ANC and TPC declined whereas the NLR and the PLR increased as compared to pre-SBRT.•Anemia along with other parameters was found to be a poor prognostic factor for local control despite treatment with SBRT to doses of >100 Gy BED.•Simple and minimally invasive methods like a peripheral blood sample can provide prognostic information even for stage-I NSCLC patients.•Patient, tumor and treatment factors along with molecular markers should be used to create risk stratification models that can guide therapy.
•本研究报告了血液学参数对已知最大的经活检证实为I期、医学上无法手术且接受立体定向体部放疗（SBRT）治疗的队列的预后预测能力。
•与SBRT治疗前相比，SBRT治疗后血红蛋白（Hb）、淋巴细胞绝对计数（ALC）、中性粒细胞绝对计数（ANC）和血小板计数（TPC）的中位数下降，而中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR）升高。
•尽管给予大于100 Gy生物等效剂量（BED）的SBRT治疗，但贫血以及其他参数被发现是局部控制的不良预后因素。
•像外周血样本这样简单且微创的方法即使对于I期非小细胞肺癌（NSCLC）患者也能提供预后信息。
•患者、肿瘤和治疗因素以及分子标志物应被用于创建可指导治疗的风险分层模型。
